Given these findings, we might expect the response to clozapine to be greater for individuals who had been so intolerant of a previous antipsychotic medication that the medication trial had to be discontinued (e.g., because of experiencing high levels of EPS or developing tardive dyskinesia) compared with individuals who had received adequate trials with first generation antipsychotic medications but had failed to respond to them.